Speakers - 2025

Biography

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, they graduated from Astrakhan State Medical University and were awarded an MD. In 1985, Suchkov maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology. In 2001, Suchkov maintained his doctorate Degree at the National Institute of Immunology, Russia.
From 1989 through 1995, Dr. Suchkov was the Head of the Lab of Clinical Immunology at Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, I was chair of the Department for Clinical Immunology at the Moscow Clinical Research Institute (MONIKI). From 1993 to 1996, Dr. Suchkov was a Secretary-in-Chief of the Editorial Board of Biomedical Science, an inter-national journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.
At present, Dr Sergey Suchkov, MD, PhD, is:
● Russian University of Medicine, Moscow, Russia
● Member, Russian Academy of Natural Sciences, Moscow, Russia
● Member, New York Academy of Sciences, USA
● Secretary General, United Cultural Convention (UCC), Cambridge, UK
Dr Suchkov is a member of the:
● American Chemical Society (ACS), USA;
● American Heart Association (AHA), USA;
● European Association for Medical Education (AMEE), Dundee, UK;
● EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU;
● ARVO (American Association for Research in Vision and Ophthalmology);
● ISER (International Society for Eye Research);
● Personalized Medicine Coalition (PMC), Washington, DC, USA

Abstract

A new and upgraded approach to diseased states and wellness and to reshape tomorrow’s healthcare whilst doing it today resulted in a new global trend in healthcare services, namely, personalized and precision medicine (PPM). PPM, as a unique entity demonstrating the integration of fundamental healthcare & life sciences, biodesign-driven biotech, translational ART, and IT Armamentarium, is based on the new developmental strategy driven by biomarkers- and targeting-related machines. So, it would be extremely useful to integrate data harvesting from different databanks for applications such as early predictive diagnostics, precise prognostication, and personalization of further treatment to thus provide more tailored measures for the disease bodies and persons at risk, resulting in improved outcomes and cost-effective use of the latest health care resources.

PPM, as being the Grand Challenge to forecast, predict, and prevent, is rooted in a big and new SCIENCE generated by the achievements of (i) Systems & Synthetic Biology, (ii) Biodesign-driven Translational
applications and biotech-driven biomanufacturing, (iii) bioindustry, and biomarketing of the next step generation. The latter, being a grand brick laid into the frame of the national bioeconomy, says and confirms that the efficiency and efficacy of the bioeconomy are determined and dictated by the innovative trends generated by fresh knowledge and their transfer into the scientific, bio-industrial, and social areas to maintain the national stability and extensive development of the country.

The core strategic tool to operate the transdisciplinary approach is rooted in a unique tandem consisting of (i) integrated platforms of Fundamental Sciences (Basics) and innovative OMIC biotechnologies on the one hand and (ii) the algorithms of Bioinformatics on the other.

The importance of PPM in the healthcare management of several diseases is well-documented. Advances in genomics and computing are transforming the capacity for the characterization of biological systems, and researchers are now poised for a precision-focused transformation in how they prepare for and respond to infectious diseases. But still, very little is known about the role of precision genomics and immunogenetics in susceptibility or resistance to infectious diseases. And despite being a forerunner, PPM is not yet routinely applied in infectious patient care.

Meanwhile, new technologies are supporting the rapid identification of infective agents and targeted approaches based on the genetic resistance of pathogens to antibiotics. For instance, recent technological advances have enabled the development of antimicrobials that can selectively target a gene, a cellular process, or a microbe of choice. These strategies bring us a step closer to developing personalized therapies that exclusively remove disease-causing infectious agents. This information can lead to revising the data banks that can be used for personalized predicting diseases, improving PPM-driven treatment, and also personalized prevention strategies specific to infectious pathogens.

PPM-driven management of infectious diseases plays a critical role in trust for government, healthcare organizations, science, and pharma. The improvement in biomedical technologies, the availability of large clinical and OMICS data, and the appropriate application of bioinformatics-related algorithms may allow precision in vaccines and public health and restore trust. For this scope, the next step, education, is a crucial step for the successful implementation of PPM in the clinic, and with this part, we would like to encourage learning about PPM and its impact in the communicable (including infectious) disease field.

Infectious disease management essentially consists of identifying the microbial cause(s) of an infection, initiating, if necessary, antimicrobial therapy against microbes, and controlling host reactions to infection. In canonical (PPM-ignored) clinical microbiology, the turnaround time of the diagnostic cycle (>24 hours) often leads to unnecessary suffering and deaths; approaches to relieve this burden include rapid diagnostic procedures and more efficient transmission or interpretation of molecular microbiology results. While genomics-supported PPM generally aims at interrogating the genomic information of a patient, drug metabolism polymorphisms, for example, to guide drug choice and dosage, PPM concepts are applicable in infectious diseases for the rapid identification of a disease-causing microbe and determination of its antimicrobial resistance profile to guide appropriate antimicrobial treatment for the proper management of the patient and, in particular, for persons at risk. The implementation of point-of-care testing for infectious diseases will require acceptance by medical authorities, new technological and communication platforms, as well as reimbursement practices such that time- and life-saving procedures become available to the largest number of patients.

PPM has indeed arrived to diagnose infectious diseases. More than that, it has arrived once and for all in the areas of clinical microbiology, molecular epidemiology, and many other areas. With the current capabilities, cost, and speed of sequencing technologies, the field has finally reached a point where rapid genomic surveillance and analysis can start to become a standard part of the response to infectious disease outbreaks. Just as broadscale human genome sequencing revolutionized the treatment of many noncommunicable diseases, pathogen genome data are poised to drive a similar revolution in the response to infectious diseases.

Healthcare is undergoing a transformation, and it is imperative to leverage new technologies to support the advent of PPM. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM and TraMed to elicit the content of the new trend. The latter would provide a unique platform for dialogue and collaboration among thought leaders and stakeholders in government, academia, industry, foundations, and disease and patient advocacy with an interest in improving the system of healthcare delivery on the one hand and drug discovery, development, and translation on the other one, whilst educating the policy community about issues where biomedical science and policy intersect